Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Phase 1/2a Study of ANPD001 in Parkinson Disease

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingPhase 1/2a Study of ANPD001 in Parkinson Disease

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingGenetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingGene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

GCC19CART for Patients With Metastatic Colorectal Cancer

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingGCC19CART for Patients With Metastatic Colorectal Cancer

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Phase 1/2a Study of ANPD001 in Parkinson Disease

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingPhase 1/2a Study of ANPD001 in Parkinson Disease

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Stem Cell Therapy for Limbal Stem Cell Deficiency

  • Post author:
  • Post published:March 25, 2026
  • Post category:

Continue ReadingStem Cell Therapy for Limbal Stem Cell Deficiency

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

  • Post author:
  • Post published:March 25, 2026
  • Post category:

Continue ReadingA Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
  • Go to the previous page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 32
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us